CINECA IRIS Institutional Research Information System

FRUTTERO, Roberta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.047
EU - Europa 7.997
AS - Asia 3.998
AF - Africa 69
SA - Sud America 63
OC - Oceania 49
Continente sconosciuto - Info sul continente non disponibili 19
Totale 24.242
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.876
CN - Cina 2.124
IT - Italia 1.394
DE - Germania 1.137
SE - Svezia 1.011
IE - Irlanda 1.003
UA - Ucraina 653
FR - Francia 621
FI - Finlandia 541
SG - Singapore 530
GB - Regno Unito 469
KR - Corea 410
PL - Polonia 307
AT - Austria 286
JP - Giappone 269
DK - Danimarca 233
VN - Vietnam 204
CA - Canada 157
IN - India 154
ID - Indonesia 104
RU - Federazione Russa 77
BE - Belgio 57
NL - Olanda 51
TW - Taiwan 47
SN - Senegal 38
BR - Brasile 37
ES - Italia 37
GR - Grecia 37
AU - Australia 36
TR - Turchia 34
CH - Svizzera 26
HK - Hong Kong 24
EU - Europa 17
IR - Iran 17
EG - Egitto 16
UZ - Uzbekistan 15
MX - Messico 14
NZ - Nuova Zelanda 12
MY - Malesia 10
RO - Romania 9
ZA - Sudafrica 9
CL - Cile 8
IQ - Iraq 8
JO - Giordania 8
BG - Bulgaria 7
SA - Arabia Saudita 7
AE - Emirati Arabi Uniti 6
CZ - Repubblica Ceca 6
NO - Norvegia 6
TH - Thailandia 6
HU - Ungheria 5
IL - Israele 5
UY - Uruguay 5
AL - Albania 4
AR - Argentina 4
HR - Croazia 4
PE - Perù 4
PT - Portogallo 4
RS - Serbia 4
CY - Cipro 3
LT - Lituania 3
MU - Mauritius 3
PH - Filippine 3
PK - Pakistan 3
AM - Armenia 2
BQ - ???statistics.table.value.countryCode.BQ??? 2
CO - Colombia 2
EC - Ecuador 2
LU - Lussemburgo 2
QA - Qatar 2
SC - Seychelles 2
SI - Slovenia 2
LB - Libano 1
MO - Macao, regione amministrativa speciale della Cina 1
MW - Malawi 1
PW - Palau 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
VE - Venezuela 1
Totale 24.242
Salva come PNG Salva come JPEG
Città #
Chandler 1.461
Ann Arbor 1.422
Beijing 1.215
Dublin 997
Fairfield 899
Ashburn 689
Houston 508
Woodbridge 471
Torino 467
Jacksonville 437
Wilmington 402
Villeurbanne 398
Dearborn 390
Singapore 366
Seattle 354
Princeton 327
Medford 302
Cambridge 301
Warsaw 294
Nyköping 285
Vienna 279
Pisa 260
Frankfurt am Main 182
Redwood City 153
Dong Ket 148
Fremont 122
Jakarta 100
Milan 97
Boston 96
Munich 95
Boardman 94
Shanghai 86
Hangzhou 74
Guangzhou 73
Nanjing 73
Santa Clara 71
Helsinki 58
Brussels 54
Norwalk 50
Ottawa 50
Verona 50
San Diego 48
New York 45
Toronto 43
Hefei 40
Taipei 38
Washington 37
Turin 35
Falls Church 34
Tokyo 34
Zhengzhou 34
Shenyang 33
Jinan 28
Phoenix 27
Lachine 26
Pune 26
Düsseldorf 25
Kunming 25
Wuhan 25
Siena 24
Nürnberg 21
Chengdu 20
Los Angeles 20
Nanchang 19
Philadelphia 19
Kharkiv 18
Monmouth Junction 17
Buffalo 16
Changsha 16
Rome 16
Silver Spring 16
Toledo 16
Xian 15
Hebei 14
Leinì 14
Nuremberg 14
Seongnam 14
Cardiff 13
Copenhagen 13
Fuzhou 13
London 13
Seoul 13
Tianjin 13
Lansing 12
Nottingham 12
Upper Marlboro 12
Bologna 11
Cairo 11
Florence 11
Dallas 10
Mountain View 10
Tappahannock 10
Amsterdam 9
Changchun 9
Des Moines 9
Paris 9
Ardabil 8
Catania 8
Dresden 8
Moscow 8
Totale 15.407
Salva come PNG Salva come JPEG
Nome #
Quinone based nitric oxide donating compounds 531
1,2,5-Oxadiazole analogues of leflunomide and related compounds 436
H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance 406
In vitro pharmacological evaluation of multitarget agents for thromboxane prostanoid receptor antagonism and COX-2 inhibition 350
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells 305
Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance 287
Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts 283
Novel small molecule protein arginine deiminase 4 (PAD4) inhibitors 278
New furoxan derivatives for the treatment of ocular hypertension 276
Doxorubicin-antioxidant multitarget drugs 266
Designing Multitarget Anti-inflammatory Agents: Chemical Modulation of the Lumiracoxib Structure toward Dual Thromboxane Antagonists-COX-2 Inhibitors. 266
Mitochondrial-targeting nitrooxy-doxorubicin: a new approach to overcome drug resistance. 263
NO-donor thiacarbocyanines as multifunctional agents for Alzheimer’s disease 257
Overcoming multidrug resistance by targeting mitochondria with NO-donating doxorubicins 257
Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors 252
New inhibitors of dihydroorotate dehydrogenase (DHODH) based on the 4-hydroxy-1,2,5-oxadiazol-3-yl (hydroxyfurazanyl) scaffold 241
A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity 227
Carnosine analogues containing NO-donor substructures: Synthesis, physico-chemical characterization and preliminary pharmacological profile 214
Edaravone derivatives containing NO-donor functions 211
A Molecular Hybrid for Mitochondria-Targeted NO Photodelivery 201
Thymopentin down-regulates both activity and expression of iNOS in blood cells of Sézary syndrome patients 198
4-Hydroxy-1,2,5-oxadiazol-3-yl Moiety as Bioisoster of the Carboxy Function. Synthesis, Ionization Constants, and Molecular Pharmacological Characterization at Ionotropic Glutamate Receptors of Compounds Related to Glutamate and Its Homologues 195
(Nitrooxyacyloxy)methyl esters of aspirin as novel nitric oxide releasing aspirins 192
Aspects of heterocyclic chemistry in developing new 1,4-dihydropyridine Ca2+-antagonists 186
Synthesis of new bicyclic analogues of glutamic acid 186
A New Synthetic Approach to Substituted β-Carboline Systems 185
Phenylsulfonylfuroxans as Modulators of Multidrug-Resistance-Associated Protein-1 and P-Glycoprotein 177
Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs 171
Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis 171
Liposomal Nitrooxy-Doxorubicin: One Step over Caelyx in Drug-Resistant Human Cancer Cells 169
New nitric oxide or hydrogen sulfide releasing aspirins 165
Amodiaquine analogues containing NO-donor substructures: Synthesis and their preliminary evaluation as potential tools in the treatment of cerebral malaria 162
Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity 162
The role of fluorine in stabilizing the bioactive conformation of dihydroorotate dehydrogenase inhibitors 160
A Nonmetal-Containing Nitric Oxide Donor Activated with Single-Photon Green Light 158
Development of a new class of potential antiatherosclerosis agents: NO-donor antioxidants 157
Furazan and furoxan sulfonamides are strong α-carbonic anhydrase inhibitors and potential antiglaucoma agents 157
Combination of PDT and NOPDT with a tailored BODIPY derivative 154
A rapid screening for cytochromes P450 catalysis on new chemical entities: cytochrome P450 BM3 and 1,2,5-oxadiazole derivatives 153
Synthesis and preliminary biological profile of new NO-donor tolbutamide analogues. 152
Anti-pseudomonas activity of 3-nitro-4-phenylfuroxan 149
Composti ibridi per il trattamento della malaria cerebrale 148
Effects of Nitric Oxide Donor Antioxidants Containing the Phenol Vitamin E Substructure and a Furoxan Moiety on Ischemia/Riperfusion Injury 148
4-Methyl-3-(arylsulfonyl)furoxans: a new class of potent inhibitors of platelet aggregation. 147
Light-Tunable Generation of Singlet Oxygen and Nitric Oxide with a Bichromophoric Molecular Hybrid: a Bimodal Approach to Killing Cancer Cells 144
Nitrooxymethyl Substituted Analogues of Celecoxib: Synthesis and Pharmacological Characterization 143
Nitrooxymethyl-Substituted Analogues of Rofecoxib: Synthesis and Pharmacological Characterization 139
Multitarget Drugs: Synthesis and Preliminary Pharmacological Characterization of Zileuton Analogues Endowed with Dual 5-LO Inhibitor and NO-Dependent Activities 136
gem-Dinitroalkyl Benzenes: A Novel Class of IOP-Lowering Agents for the Treatment of Ocular Hypertension 135
A Potent and Selective P-gp Modulator for Altering Multidrug Resistance Due to Pump Overexpression 134
NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties 132
Synthesis and biological evaluation of the first example of NO-donor histone deacetylase inhibitor 132
A multi-photoresponsive molecular-hybrid for dual-modal photoinactivation of cancer cells 132
Searching for new NO-donor aspirin-like molecules: furoxanylacyl derivatives of salicylic acid and related furazans 129
Synthesis and in vitro antimicrobial activities of new (cyano-NNO-azoxy)pyrazole derivatives 128
A new class of NO-donor H3-Antagonists 127
Searching for new NO-donor Aspirin-like molecules: a new class of nitrooxy-acyl derivatives of salicylic acid 127
Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs) 127
Water-Soluble Nitric-Oxide-Releasing Acetylsalicylic Acid (ASA) Prodrugs 127
A Nitric Oxide-Donor Furoxan Moiety Improves the Efficacy of Edaravone against Early Renal Dysfunction and Injury Evoked by Ischemia/Reperfusion 125
Amphiphilic NO-Donor Antioxidants 125
Synthesis and Biological Evaluation of N2-Substituted 2,4-Diamino-6-cyclohexylmethoxy-5-nitrosopyrimidines and Related 5-Cyano-NNO-azoxy Derivatives as Cyclin-Dependent Kinase 2 (CDK2) Inhibitors 124
Fluorescent Nitric Oxide Photodonors Based on BODIPY and Rhodamine Antennae 122
Multitarget Drugs: Focus on the NO-donor hybrid drugs 120
Nitric Oxide Donor Doxorubicins Accumulate into Doxorubicin-Resistant Human Colon Cancer Cells Inducing Cytotoxicity 119
Novel R-roscovitine NO-donor hybrid compounds as potential pro-resolution of inflammation agents 118
Molecular dynamics simulations reveal the determinants of cyclin-dependent kinase 2 inhibition by 5-nitrosopyrimidine derivatives 118
Novel Antioxidant Agents Deriving From Molecular Combination of Vitamin C and NO-donor moieties 117
NO-Donor Melatonin Derivatives: Synthesis And In Vitro Pharmacological Characterization 117
Structural and biological characterization of new hybrid drugs joining an HDAC inhibitor to different NO-donors 115
New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni 113
Synthesis of Some Novel Organic Nitrates and Comparative in Vitro Study of Their Vasodilator Profile 112
NO-donors: focus on furoxan derivatives 110
A molecular hybrid producing simultaneously singlet oxygen and nitric oxide by single photon excitation with green light 110
Use of Nitric Oxide Releasing Furoxan System in the Design of "Hybrids": Substitution of Furoxan Moieties for the Furan Ring in Prazosin 109
Carnosine analogues containing Phenol substructures 109
Design, Biological Evaluation, and Molecular Modeling of Tetrahydroisoquinoline Derivatives: Discovery of A Potent P-Glycoprotein Ligand Overcoming Multidrug Resistance in Cancer Stem Cells 109
NO-Donor Phenols: A New Class of Products Endowed with Antioxidant and Vasodilator Properties 105
Inhibition of Human Placenta Glutathione Transferase P1-1 by the Antibiotic Calvatic Acid and its Diazocyanide Analogue: Evidence for Multiple Catalytic Intermediates 104
New tetrahydroisoquinoline derivatives overcome pgp activity in brain-blood barrier and glioblastoma multiforme in vitro 104
New potential uroselective NO-donor a1-antagonists 102
Tuning the Hydrophobicity of a Mitochondria-Targeted NO Photodonor 102
Activité contre les Microorganismes de dex Pyrazolyldiazène carbonitriles Oxyde-2 100
A new furoxan NO-donor rabeprazole derivative and related compounds 98
A new class of ibuprofen derivatives with reduced gastrotoxicity 98
Characterization of a new compound, S35b, as a guanylate cyclase activator in human platelets. 97
[3-(1H-Imidazol-4-yl)propyl)guanidines Containing Furoxan Moieties: A New Class of H3-Antagonists Endowed with NO-Donor Properties 97
Leishmanicidal Activity of Novel Synthetic Furoxan and Benzofuroxan Derivatives 96
Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma 96
A novel hybrid aspirin-NO releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages 96
ALPHA(1)-ADRENOCEPTOR BLOCKING ACTIVITY OF SOME RING-OPEN ANALOGS OF PRAZOSIN 95
Different multitarget approaches to manage coxibs associatedcardiovascular risk. Design and synthesis of new lumiracoxibderivatives 95
Synthesis and Structure of a Trimer of the Furoxan System with High Vasodilator and Platelet Antiaggregatory Activity 95
Synthesis, physico-chemical characterization, andbiological activities of new carnosine derivatives stablein human serum as potential neuroprotective agents 94
6-Cyclohexylmethoxy-5-(cyano-NNO-azoxy)pyrimidine-4-amine: A new scaffold endowed with potent CDK2 inhibitory activity 94
Nitrooxyacyl Derivatives of Salicylic Acid: Aspirin-Like Molecules that Covalently Inactivate Cyclooxygenase-1 94
Activity of calvatic acid and its analogs against Helicobacter pylori 91
DNA-targeted NO release photoregulated by green light 90
Furoxan analogues of the histamine H3-receptor antagonist imoproxifan and related furazan derivatives 88
A Directed Synthesis of Alkyl, Aryl, and Heteroaryl-ONN-azoxycyanides 88
Totale 16.112
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.096
article - articoli 0
book - libri 0
conference - conferenze 10.023
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.119
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.519 0 0 0 449 295 567 467 289 470 439 283 260
2020/20212.736 241 187 186 142 248 170 185 155 412 222 191 397
2021/20223.699 217 184 237 320 245 118 287 252 128 288 755 668
2022/20234.145 507 396 123 393 312 1.016 459 235 367 101 151 85
2023/20241.835 209 270 123 90 141 301 86 89 25 113 134 254
2024/2025684 75 324 215 70 0 0 0 0 0 0 0 0
Totale 25.110